High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
621.91M
-3.2%
-0.302
+12.66%
627.78M
-1.99%
-0.230
+34.9%
637.01M
-0.54%
-0.217
-11.26%
Estimates Revision
The market is revising Downward the revenue expectations for Teladoc Health, Inc. (TDOC) for FY2025, with the revenue forecasts being adjusted by -0.23% over the past three months. During the same period, the stock price has changed by 12.71%.
Revenue Estimates for FY2025
Revise Downward
-0.23%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+6.59%
In Past 3 Month
Stock Price
Go Up
+12.71%
In Past 3 Month
16 Analyst Rating
0Wall Street analysts forecast TDOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TDOC is 8.46 USD with a low forecast of 7.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
14 Hold
0 Sell
Hold
0Current: 8.070
Low
7.00
Averages
8.46
High
12.00
0Current: 8.070
Low
7.00
Averages
8.46
High
12.00
BofA
Neutral
maintain
$7
2025-07-03
New
Reason
BofA
Price Target
$7
2025-07-03
New
maintain
Neutral
Reason
BofA raised the firm's price target on Teladoc to $8.75 from $7 and keeps a Neutral rating on the shares. Teladoc's recent acquisitions of Catapult and Uplift provide optionality to drive higher revenue per member, but it will take both time and execution to improve the revenue growth outlook, the analyst tells investors in a research note. BofA remains cautious on full-year guidance and momentum into 2026 but views recent acquisitions as potential catalysts for growth.
BofA
Neutral
downgrade
$8 -> $7
2025-05-28
Reason
BofA
Price Target
$8 -> $7
2025-05-28
downgrade
Neutral
Reason
BofA lowered the firm's price target on Teladoc to $7 from $8 and keeps a Neutral rating on the shares. In April, global BetterHelp MAUs declined 6.1% year-over-year, further decelerating from low single-digit declines in the prior month, according to the analyst, who cites lower peer multiples for the firm's lowered price target. The firm remains cautious on the near-term outlook, but could see investments for future growth driving greater patient engagement over time, the analyst added.
Truist
Hold
downgrade
$10 -> $9
2025-05-27
Reason
Truist
Price Target
$10 -> $9
2025-05-27
downgrade
Hold
Reason
Truist lowered the firm's price target on Teladoc to $9 from $10 and keeps a Hold rating on the shares. The firm is updating its model after the company's Q1 results with expectations of slightly lower 2026 EBITDA, the analyst tells investors in a research note. Longer term, Truist notes that with about 90M U.S. members having access to its offerings, Teladoc has the scale and depth to take advantage of various growth opportunities across the healthcare continuum.
Citi
Neutral
downgrade
$11
2025-04-25
Reason
Citi
Price Target
$11
2025-04-25
downgrade
Neutral
Reason
Citi lowered the firm's price target on Teladoc to $8.75 from $11 and keeps a Neutral rating on the shares. The firm also added an "upside 30-day short-term view" on the shares. It is likely that BetterHelp beats on sales this quarter, the analyst tells investors in a research note. Citi does not expect any change to Teladoc's guidance and, given consumer spending concerns, it thinks management will strike a cautious tone. However, given bearish sentiment, "this should be good enough" for a positive stock price reaction, contends the firm.
Jefferies
Glen Santangelo
Hold
Maintains
$10 → $8
2025-04-21
Reason
Jefferies
Glen Santangelo
Price Target
$10 → $8
2025-04-21
Maintains
Hold
Reason
B of A Securities
Allen Lutz
Hold
Maintains
$9.5 → $8
2025-04-11
Reason
B of A Securities
Allen Lutz
Price Target
$9.5 → $8
2025-04-11
Maintains
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Teladoc Health Inc (TDOC.N) is -7.95, compared to its 5-year average forward P/E of -52.83. For a more detailed relative valuation and DCF analysis to assess Teladoc Health Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-52.83
Current PE
-7.95
Overvalued PE
20.13
Undervalued PE
-125.79
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
41.64
Current EV/EBITDA
6.49
Overvalued EV/EBITDA
86.83
Undervalued EV/EBITDA
-3.54
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
4.79
Current PS
0.58
Overvalued PS
10.18
Undervalued PS
-0.60
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 368.49% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 368.49% over the last month.
Sold
Bought
TDOC News & Events
Events Timeline
(ET)
2025-06-23
10:18:33
Teladoc 'a coiled spring' whose CEO 'just flipped the script,' Citron says
2025-04-30 (ET)
2025-04-30
16:12:57
Teladoc acquires UpLift Health for $30M in cash
2025-04-30
16:11:54
Teladoc sees Q2 EPS (40c)-(20c), consensus (26c)
Sign Up For More Events
Sign Up For More Events
News
Preview
2.0
06-26NASDAQ.COMWhat's Happening With HIMS Stock?
Preview
8.0
06-25NASDAQ.COMNoteworthy Tuesday Option Activity: MSTR, WGS, TDOC
Preview
4.5
06-24NASDAQ.COMStocks Supported as Tensions Ease in the Middle East
Sign Up For More News
People Also Watch
FAQ
What is Teladoc Health Inc (TDOC) stock price today?
What is Teladoc Health Inc (TDOC)'s business?
What is the price predicton of TDOC Stock?
What is Teladoc Health Inc (TDOC)'s revenue for the last quarter?
What is Teladoc Health Inc (TDOC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Teladoc Health Inc (TDOC)'s fundamentals?
How many employees does Teladoc Health Inc (TDOC). have?